Abstract

Our research hypothesis is that AstraZeneca’s sustainability practices have improved their business performance and have increased the company's ability to become more innovative. Our team used the case study research method to collect and analyze data on how AstraZeneca carries out their sustainability practices, to test our hypothesis. The data was collected from AstraZeneca’s annual sustainability reports, press releases, and other third-party media. The findings were evaluated using the Global Reporting Initiative Guidelines (GRI) and business strategy concepts, such as creating shared value, materiality issues, and the Triple Bottom Line (TBL). Based on our findings, we believe that the practices of AstraZeneca support our hypothesis.